Drug Safety

      MANDARA
      Mepolizumab v benralizumab for EGPA

      BEN is non-inferior
      Secondary outcomes- less eosinophils and more pts compl

      Eric Dein ericdeinmd

      10 months 3 weeks ago
      MANDARA Mepolizumab v benralizumab for EGPA BEN is non-inferior Secondary outcomes- less eosinophils and more pts completely off GCs Now approved for EGPA Year in Review #ACR24 Pillinger @RheumNow https://t.co/ThLziABvzu
      Abatacept for GPA?

      Tx with Abacept did NOT significantly reduce rates of treatment failure compared to GC + PBO (backgr

      Brian Jaros, MD Dr_Brian_MD

      10 months 3 weeks ago
      Abatacept for GPA? Tx with Abacept did NOT significantly reduce rates of treatment failure compared to GC + PBO (background DMARD allowed) in non-severe, relapsing GPA Continued need for tx options in non-severe relapsing dz @RheumNow #ACR24 Abstract #0823 https://t.co/7GfprUzoL7
      RA pearls from #ACR24 review course:
      1. Remission is DRUG maintained-Ok to reduce MTX dose while on TNFi.
      2. Multimorbid

      Adela Castro AdelaCastro222

      10 months 3 weeks ago
      RA pearls from #ACR24 review course: 1. Remission is DRUG maintained-Ok to reduce MTX dose while on TNFi. 2. Multimorbidity=Poor outcomes, High risk for mortality. 3. Can RA be truly prevented or we are delaying the inevitable? https://t.co/111w1Myqrg
      Risk for atypical femoral fracture:

      🚨Asian race - 4-6x higher risk
      Duration of use is greater risk than older age

      H

      Eric Dein ericdeinmd

      10 months 3 weeks ago
      Risk for atypical femoral fracture: 🚨Asian race - 4-6x higher risk Duration of use is greater risk than older age Higher risk when given for osteoporosis than cancer treatment - Compare: osteonecrosis of jaw more common with cancer Rx #ACR24 Review Course @RheumNow https://t.co/V8cD5QWNGp
      guidelines.jpg (keep)
      British Society Guidelines for Managing Behçet’s Disease
      1 year ago
      An exhaustive, full read guideline from the British Association of Dermatologists (BAD) and the British Society for Rheumatology (BSR) on the management and treatment of Behçet’s disease (BD) in 2024 has been published in Rheumatology.

      Catch up on Conference Podcasts

      ×